
Sign up to save your podcasts
Or


In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management.
This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.
By OncologyEducationIn this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management.
This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.